The Bram and Elaine Goldsmith and the Medallions Group Endowed Chairs in Gene Therapeutics to PRL and MGC, respectively. The Drown Foundation; The Linda Tallen & David Paul Kane Foundation and the Board of Governors at CSMC. The authors thank the Chunyan Liu at Cedars Sinai Medical Center/UCLA for the preparation of the Ad-IFN and the Comparative Pathology Shared Resource of the University of Minnesota Masonic Cancer Center for preparation of the histological sections. “
“Over the past two decades, many efforts have been made to struggle infectious diseases; new vaccines will be Quizartinib cell line thus available until 2015 and their introduction will represent a central issue for decision

makers worldwide [1]. Usually the introduction of new vaccines brings about some problems and questions, such as the choice of the vaccines to introduce or implement, the economic resources to employ and the vaccination services to be provided. Despite the amount of vaccines available in the future, health economic resources are limited and every choice in Public Health should

be weighed in order to best use financial and human means. In 2002, vaccine spending accounted for only 1.7% of the total pharmaceutical market and UNICEF estimated that 34 million children were not reached by universal routine immunisation. Economic resources would be provided and best employed to meet the goal of universal immunisation in developing countries over the 2004–2014 period [2]. The vaccines introduction

process, if correctly done, should be based on different issues: the safety and efficacy of VE-821 vaccine, the epidemiological context and the economic impact of vaccination. The epidemiological approach lets measure the burden of disease and the clinical benefit of vaccine. According to economic approach, budget impact analysis and cost-effectiveness analysis could lead decision making about vaccines introduction. In a such complicated scenario, the Health Technology Assessment (HTA) approach could represent an innovative and effective tool. The HTA evaluation, in fact, is comprehensive of epidemiological and economic evaluations and enriched with analysis of other issues like biotechnological, organisational, Oxymatrine social, legal and bioethical ones [3]. The relation between HTA and vaccines has not been well developed until now. However, there is increasing evidence that applying HTA to the evaluation process of introducing new vaccines could be a useful strategy both to meet population health needs and best employ economic resources [4]. The aim of this study was to give an example of the HTA approach to evaluate the introduction of a new vaccine that potentially could have a great impact on population health. In this view, considering all the aspects related to the introduction of a new vaccine, a HTA report could represent a new important tool to support decision makers in order to better allocate economic resources and maximise healthcare services [3].